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Objective: Datasets regarding patients with abdominal aortic aneurysm (AAA) have almost universally been restricted to single
geographic regions. We aimed to obtain data on the risk factor profile and cardiovascular (CV) co-morbidity among multi-ethnic
patients with known AAA in the global REACH (REduction of Atherothrombosis for Continued Health) Registry.
Methods: The REACH Registry is an international, prospective, observational out-patient registry enrolling out-patients
>45 years of age with established coronary artery disease (CAD), cerebrovascular disease (CVD) or peripheral arterial
disease (PAD) or with at least three atherothrombotic risk factors. This report includes observations pertaining to 68,236
out-patients enrolled in 44 countries.
Main outcome measures: Gender, ethnic origin, CV risk factors, established atherosclerotic disease (CAD, CVD and PAD)
at baseline, and CV outcome events at 1-year were compared in patients with and without AAA.
Results: An AAA was reported in 1722 (2.5%) of 68,236 out-patients enrolled in the REACH Registry. Older age (73 
8 vs 68  10, P < .0001), male gender (81% vs 63%, P < .0001), White ethnicity (79% vs 67%, P < .0001) and a history
of smoking (81% vs 55%, P < .0001) were independently related to the diagnosis of AAA. There was a weaker association
with hypertension or hypercholesterolemia, and an inverse relation with diabetes. Fatal and non-fatal coronary and
cerebrovascular event rates were not different between the AAA and non-AAA cohorts, but individuals with AAA suffered
increased rates of other cardiovascular deaths (1.39% vs 0.94%, P  .0135), hospitalizations for atherothrombotic events
(14.1% vs 9.3%, P < .0001) due to increased rates of revascularization procedures, and new or worsening PAD (3.7% vs
1.3%, P < .0001) at 1-year follow-up.
Conclusion: This study, the largest published to date, presents the CV risk profile and outcome of patients with an
established diagnosis of AAA from a cohort of patients with either overt manifestations of CV disease or multiple risk
factors, and further defines these patients in a multi-ethnic, global context. ( J Vasc Surg 2008;48:808-14.)Abdominal aortic aneurysms (AAA) compared with
established atherothrombotic disease (ie, coronary artery
[CAD], cerebrovascular disease [CVD], or peripheral arte-
rial disease [PAD]) are characterized by distinct cardiovas-
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808cular (CV) risk factor profiles, as demonstrated in the
Aneurysm Detection and Management (ADAM) study1,2
and the UK Small Aneurysm Trial.3 These distinctions
imply that the underlying pathophysiology of AAA differs
from CAD, CVD, and PAD, and some studies support the
hypothesis that AAA may not be a direct manifestation of
atherothrombosis.4-6 On the other hand, AAA and estab-
lished atherothrombotic disease often coincide, with ad-
vanced age, male gender, smoking, and family history iden-
tified as common risk factors linking these disease
entities.4,5,7-9 The etiological role of dyslipidemia and hy-
pertension remains less precisely defined,2 with some stud-
ies claiming a relationship with AAA and others reporting a
lack of association.8
Screening programs in the United States and Europe
have shown that 5% of men older than 65 have an occult
AAA.10 Individuals with AAA detected by screening rarely
present with an aortic diameter associated with a short-term
risk of aneurysm-related death (eg, from rupture), but
current data suggest that many individuals with AAA suffer
co-existing atherothrombotic risk such that coronary heart
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jor increased CVmorbidity andmortality burden.11,12 Late
survival of patients with AAA is significantly lower than that
of age- and sex-matched non-AAA populations, even after
successful AAA repair.13-15
The objective of this analysis was to investigate the
prevalence of atherothrombotic risk factors; concomitant
non-aortic CV disease; and CV ischemic event rates in a
large, prospectively defined population with an established
diagnosis of AAA compared with the non-AAA population
in the REduction of Atherothrombosis for Continued
Health (REACH) Registry, the largest worldwide registry
of out-patients at high risk of atherothrombotic events.
METHODS
The REACH Registry is a multinational, prospective,
observational registry of out-patients at high risk of, or with
established, atherothrombosis. The design of the REACH
Registry has been published previously.16,17 In summary,
68,236 consecutive out-patients aged 45 or older with
established CAD, CVD, or PAD, or with at least three
atherothrombotic risk factors were enrolled fromDec 2003
to Dec 2004, at over 5000 study sites in 44 countries
throughout the world.17 Baseline characteristics including
age, gender, ethnic origin, history, and treatment of classi-
cal atherothrombotic risk factors, measured blood pressure,
fasting blood glucose, total cholesterol, and presence of
established atherothrombotic disease (ie, CAD, CVD, and
PAD) were assessed in patients with an established diagno-
sis of known AAA (AAA population) and without diagnosis
of AAA (non-AAA population) based on a pre-hoc hypoth-
esis that differing baseline risk factors and CV outcomes
would be observed during follow-up. Definitions of base-
line characteristics were at the discretion of the treating
physician, for example labelling was based on medical his-
tory or medication, suggesting that a minority of patients
on lipid-lowering or antihypertensive drugs do not have the
according risk factor. Polyvascular disease was defined as
established atherothrombotic disease in more than one
vascular territory (ie, CAD, CVD, and PAD). Risk factors
that were documented in the medical record, or for which
patients were receiving treatment at the time of study
enrollment, were considered, including treated diabetes
mellitus, systemic blood pressure 150 mmHg despite
therapy for at least 3 months, hypercholesterolemia treated
with medication, and current smoking (defined as 15
cigarettes per day on average within the last month before
entry in the REACH Registry). The diagnosis of AAA was
based on documentation by the treating physician and not
on systematic screening. Primary aortic imaging was not
performed in this large international cohort.
At 12 3months from enrollment, data were collected
from participating physicians regarding patients’ clinical
outcomes, vascular procedures, weight, and current smok-
ing, as well as chronic medications taken regularly since
baseline. The current report is based on a database lock of
July 21, 2006 for analysis of the 1-year follow-up. Events
were not adjudicated, however, the diagnosis of ischemicstroke or transient ischemic attack (TIA) had to be based on
a neurologist or hospital report. Any CV death included
fatal stroke, fatal myocardial infarction (MI) and other CV
death. “Other CV death” included other death of cardiac
origin, pulmonary embolism, any sudden death including
unobserved and unexpected death (eg, while sleeping)
unless proven otherwise by autopsy, death following a
vascular operation, vascular procedure, or amputation (ex-
cept for trauma or malignancy), death ascribed to heart
failure, death following a visceral or limb infarction, or any
other death that was not definitely ascribed to a nonvascular
cause or hemorrhage. Any MI or stroke followed by death,
whatever the cause, in the subsequent 28 days was consid-
ered a fatal MI or fatal stroke. A new diagnosis of PAD was
documented by an abnormal ankle-brachial index (ABI) or
other objective test. Worsening of PAD included deterio-
ration of pre-existing claudication, or new episode of
chronic critical leg ischemia (Appendix, online only).
The REACHRegistry complies with the Declaration of
Helsinki; the study design was approved by the institutional
review board according to local regulations in each partic-
ipating country and all patients included in the analysis
provided signed informed consent.
Statistical analysis. Continuous variables are ex-
pressed as mean (SD). Categorical variables are expressed as
frequencies and percentages. Comparisons between cate-
gorical variables were performed using the Pearson 2 test
and trend test adjusted on age and sex were done using
Cochran-Mantel-Haenszel statistics to compare across
groups. The t-test was used to compare continuous vari-
ables. Adjustment for age and sex was made using a multi-
ple logistic model giving odds ratio (OR) with their 95%
confidence interval (CI) and the least-square mean of the
adjusted logit for each percentage. All event rates are cal-
culated with a Cox model after adjustment for age and sex.
Statistical significance was considered a two-tailed proba-
bility of .05. Statistical analysis was performed using a
SAS software version 9 (SAS Institute Inc., Cary, NC).
RESULTS
Among 68,236 patients enrolled in the REACH Reg-
istry, 1722 (2.52%) patients had an established diagnosis of
known AAA. The prevalence of AAA was more than dou-
bled in patients with symptomatic atherothrombosis com-
pared with patients with 3 atherothrombotic risk factors
(1574 vs 148; 2.8% vs 1.2%, respectively).
An AAA diagnosis was absent or unknown in 60,057
and 6457 patients, respectively. Demographic baseline data
were comparable in patients with either absent or unknown
AAA status and these two groups were merged to represent
the non-AAA population (n  66,514). Indication of
presence or absence of AAA was independent from physi-
cian specialty in 87% of known AAA cases enrolled, mean-
ing that a similar proportion of cases with or without AAA
were enrolled by a particular specialist group. A selection
bias was noticeable in a small group of specialists enrolling
15% of the overall and 13% of the AAA REACH popula-
tion, respectively. Endocrinologists enrolled 0.8% of all
ndard
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out AAA; neurologists enrolled 2.8% vs 9.6%, indicating a
proportional reduction in the expected frequency of a
diagnosis of AAA; general surgeons enrolled 6.4% vs 2.1%;
and vascular physicians enrolled 2.5% vs 1.1% indicating a
proportional increase in the expected frequency of a diag-
nosis of AAA. This selection bias was negligible for the
overall analysis as it represented only a small proportion of
the total REACH population.17
Compared with the non-AAA cohort, the AAA cohort
was older (73  8 vs 68  10 years of age, P  .0001),
more often male (81% vs 63%, P  .0001; Table I, and of
White ethnicity (79% vs 67% P  .0001; Table II).
The relative probability of AAA according to increasing
age groups in the REACH Registry is shown in Fig 1 (P 
.0001). Percentage of AAA by region (adjusted on age, sex,
diabetes, hypertension, hypercholesterolemia, and smok-
ing) is shown in Table III. In a multivariate logistic regres-
sion analysis including age, gender, and atherothrombotic
risk factors, the relationship between AAA and ethnic ori-
gin remained independent and statistically significant.
Table I. Baseline demographic characteristics of the AAA
Characteristic AAA (n  1
Male (%) 80.66
Mean age  SD (years) 73.36  7
Smoking
Current (%) 20.85
Former (%) 60.16
Never (%) 16.84
Unknown (%) 2.15
Diabetes
History (%) 29.44
Treated (%) 23.94
FBS  126 mg/dL (%) 20.31
Mean glucose  SD (mg/dL) 110.92  3
Hypercholesterolemia
History (%) 74.48
TC (200 mg/dL), % 33.31
Mean cholesterol  SD (mg/dL) 186.25  4
Hypertension
History (%) 83.45
measured  140/90 mmHg 44.78
Mean systolic BP  SD (mmHg) 135.86  1
Mean diastolic BP  SD (mmHg) 76.21  1
FBS, fasting blood sugar; TC, total cholesterol; BP, blood pressure; SD, sta
Table II. Ethnicity of the AAA and non-AAA populations
Ethnicity, % (95% CI) AAA (n  1722)
White 78.90 (76.78; 80.87)
Hispanic 2.29 (1.65; 3.17)
Asian 13.17 (11.57; 14.96)
African American 1.97 (1.38; 2.79)
Other/Multiple 3.67 (2.84; 4.74)
Not available 196
AAA, abdominal aortic aneurysm; CI, confidence interval.Smoking had a strong association with AAA after adjust-ment for age and gender (OR 3.40 [2.97-3.89], P 
.0001). This association was less marked for hypertension
(OR1.29 [1.11-1.48],P .0006), andhypercholesterolemia
(OR1.24 [1.10-1.40],P .0005).Diabetesmellitus showed
a strong and striking negative associationwith the diagnosis of
Fig 1. Increasing risk of AAA shown in sex adjusted age groups.
cmd  Cochran-Mantel-Haenszel.
non-AAA populations in the REACH Registry
Non-AAA (n  66,514) P-value
63.23 .0001
68.45  10.12 .0001
.0001
14.61
39.85
42.45
3.09
44.41 .0001
40.63 .0001
30.90 .0001
121.39  46.14 .0001
72.10 .0297
39.49 .0001
192.93  46.73 .0001
81.77 .0741
50.15 .0001
137.88  19.46 .0001
78.46  11.23 .0001
deviation, AAA, abdominal aortic aneurysm.
he REACH Registry
Non-AAA (n  66,514) Total (n  68,236)
66.92 (66.54; 67.29) 67.21 (66.84; 67.57)
5.12 (4.95; 5.30) 5.06 (4.89; 5.23)
20.33 (20.02; 20.65) 20.16 (19.85; 20.47)
4.65 (4.49; 4.82) 4.59 (4.42; 4.75)
2.98 (2.84; 3.11) 2.99 (2.86; 3.13)
5254 5450
2  131.13, P  .0001and
722)
.83
2.64
3.84
8.98
1.24in tAAA (OR 0.59 [0.53-0.66], P .0001; Table IV).
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botic disease, the co-prevalence of AAA was highest among
patients with PAD (6.6%, 550 of 8322 patients) compared
with patients with CAD (3.0%, 1218 of 40,450 patients),
or with CVD (2.2%, 425 of 18,992 patients), respectively.
Polyvascular disease was twice as frequent in patients with
AAA as in patients without: a third of patients with AAA
also had established symptomatic atherothrombosis in
more than one vascular bed, in addition to AAA (31.6% in the
AAA vs 15.5% in the non-AAA cohorts, P .0001; Fig 2).
More patients in the AAA population were treated with
antihypertensive drugs and lipid lowering agents as com-
pared with those without AAA (Table V). Patients with
Table III. Percentage of AAA by region (adjusted on age
smoking)
North
America
Latin
America
Western
Europe
Eastern
Europe
1.9% 1.4% 1.9% 0.6%
2 P  .0001.
Table IV. Significant predictors related to the diagnosis
of AAA (multivariate analysis)
Variable OR CI 95% P-value
Age (65 years) 1.07 [1.061; 1.073] .0001
Male sex 1.96 [1.713; 2.231] .0001
Ethnicity: White vs other 1.46 [1.282; 1.656] .0001
Diabetes 0.59 [0.525; 0.658] .0001
Hypertension 1.29 [1.113; 1.483] .0006
Hypercholesterolemia 1.24 [1.099; 1.399] .0005
Current or former smoker
vs never smoker 3.40 [2.974; 3.894] .0001
OR, odds ratio; CI, confidence interval.
Fig 2. Proportional prevalence of asymptomatic (risk factors only),
and established atherothrombotic disease in a single vascular bed or in
more than one vascular bed (polyvascular disease) in patients with or
without AAA in the REACH Registry. 1 location  established
atherothrombotic disease in a single vascular bed (i.e. CAD, CVD
or PAD); 2 or 3 locations  established atherothrombotic disease
in two or three vascular beds (various combinations possible).AAA were also more often treated with oral vitamin Kantagonists (18.8% vs 12.2%, P  .0001), which explains
the overall more frequent use of antithrombotics in the
AAA group (89.0% vs 86.2%, P  .0007; Table V).
One-year CV outcomes and other CV disease rates in
the AAA cohort compared with the non-AAA cohort are
presented in Table VI. Although rates of fatal and non-fatal
coronary and cerebrovascular events were not significantly
different between the AAA and non-AAA cohorts, there
were significantly higher rates of other CV deaths (1.4% vs
0.9%, P  .0135), hospitalizations for atherothrombotic
events (14.1% vs 9.3%, P  .0001) in particular revascular-
ization procedures (coronary angioplasty [3.6% vs 2.6%,
P  .0197], carotid surgery [0.82% vs 0.45%, P  .024],
peripheral bypass surgery [2.6% vs 0.7%, P .0001], other
peripheral interventions [3.8% vs 1.0%, P  .0001]) and
new or worsening PAD (3.7% vs 1.3%, P  .0001) in
individuals with AAA (Table VI).
DISCUSSION
An AAA is prevalent, associated with atherothrombotic
risk factors and clinical disease, and linked with high rates of
CV ischemic events. However, previous datasets of patients
with AAA have almost universally been limited to single
geographic regions and comprised cohorts with limited
ethnic diversity so that global validity remains to be
shown.1-3,18-20 The REACH Registry provides a unique
opportunity to analyze these features of AAA in a global
population as well as an opportunity to compare clinical
diabetes, hypertension, hypercholesterolemia, and
Middle
East Asia Australia Japan
0.3% 0.5% 1.4% 1.7%
Table V. Baseline medications among AAA and
non-AAA populations in the REACH Registry
Medication use, %
AAA
(n  1722)
Non-AAA
(n  66,514) P-value
Aspirin 65.21 67.29 NS
Other antiplatelet 25.57 24.73 NS
Dual antiplatelet therapy 13.38 13.21 NS
Vitamin K antagonists 18.80 12.16 .0001
Any antithrombotic therapy* 89.01 86.15 .0007
Statins 71.15 69.29 NS
Any lipid lowering drug 77.25 75.09 .0402
ACE-inhibitor 44.11 45.22 NS
Angiotensin II inhibitors 20.98 22.96 .0542
Calcium channel blockers 37.00 33.91 .0075
Diuretics 45.05 40.26 .0001
Betablockers 50.58 47.41 .0095
Any antihypertensive therapy 93.14 91.27 .0065
ACE, angiotensin converting enzyme; AAA, abdominal aortic aneurysm.
*Either oral vitamin K antagonists or antiplatelet agents., sex,characteristics in a very large cohort of 1722 patients with
onfide
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with either overt manifestations of CV disease or multiple
risk factors. Analysis of REACHRegistry data confirms that
AAA occurs most frequently in older White males with a
smoking history,1,2,4,5,21 and a prevalence more than dou-
ble in patients with symptomatic atherothrombosis com-
pared with patients with atherothrombotic risk factors only.
A statistically significant ethnic association with AAA,
independent from risk factor prevalence, age, and gender,
was observed across all geographic regions in the REACH
Registry. This observation supports previous studies imply-
ing that a genetic component contributes to the develop-
ment of AAA, as has also been observed in first order
relatives of individuals with known AAA.22 The association
of AAAwith concomitant lower extremity PADmay be due
to the strong pathophysiologic association of both AAA
and PADwith smoking. Both the aorta and lower extremity
arteries are especially susceptible to injury by exposure to all
forms of tobacco and cigarette smoking in particular.4,23-25
In accordance with prior studies, we found less robust
evidence that hypercholesterolemia8 or hypertension9 are
strongly related to the presence of AAA.1,2,10,26-28 As
medications prescribed for hypercholesterolemia and hy-
pertension may have affected the development of AAA, the
relationship between these risk factors and AAA presence is
difficult to assess. Prospective studies have shown that, al-
though hypertension has a weak association with AAA preva-
lence,mortality fromAAA increases with high blood pressure.
As a result, hypertension may be a relatively poor predictor of
the risk of developing AAA in the general population, but an
important risk factor for rupture in patients with established
AAA.29 An interesting observation from our analysis is the
strong inverse relationship of AAA with diabetes, in accor-
dance with a recent review by Weiss et al30 who reported a
Table VI. One-year cardiovascular outcome events (adjus
populations of the REACH Registry
One-year outcome events, % [95% CI]
CV death
Fatal-MI
Fatal-stroke
Other CV death
Non-fatal stroke
Non-fatal MI
CV death/MI/stroke
CV death/MI/stroke/CV hospitalization
Hospitalization
Unstable angina/TIA/stroke
Other ischemic arterial event
Bleeding
Coronary: Endovascular or surgical (CABG/ angioplasty/stenting
Carotid: Endovascular or surgical (surgery or angioplasty/stenting
New diagnosis or worsening of PAD
PAD: Endovascular or surgical (bypass graft or amputation or oth
AAA, abdominal aortic aneurysm;CABG, coronary artery bypass graft;CI, c
arterial disease; TIA, transient ischemic attack.lower prevalence of AAA in patients with diabetes in sixstudies. This is particularly notable, as PAD is related to
smoking and diabetes, but with considerable differences in
anatomical manifestation.31 While the aorto-iliac segment
seems to be particularly susceptible to injury by smoking,
the distal arterial tree appears to be most susceptible to
diabetes-related injury. It is unclear whether diabetic and
non-diabetic individuals differ in abdominal aortic wall
constitution or if other factors are more relevant, although
this might help to further clarify the underlying pathophys-
iology and guide the development of novel pharmacologi-
cal treatment options. Of note, whereas proteolysis and
matrix destruction are characteristic of aneurysmal disease,
the increased matrix volume characteristic of diabetic angi-
opathy might also be the case in the abdominal aorta.32
Despite these observations, assessment of these differences
has drawn little attention in AAA research.
Although these data confirm a high prevalence of
classical atherothrombotic risk factors, such as smoking,
hypertension, and hyperlipidemia within the AAA popu-
lation, the relationship does not include diabetes, which
was found to be significantly less prevalent in individuals
with AAA than in patients with other atherothrombotic
syndromes. Thus, this survey further underlines the hy-
pothesis that AAA may represent an arterial disease with a
pathophysiology dependent, only in part, on standard
atherothrombotic risk factors.
The REACH Registry includes a very large population
of individuals with known AAA from a cohort of 1722
patients with either overt manifestations of CV disease or
multiple risk factors, and evaluates the outcome of these
patients with regard to CV event rates. While clinicians and
patients perceive AAA-related death (eg, rupture and peri-
procedural CV events) as the cause of mortality in large
AAAs, data from the REACH Registry demonstrates that
or age, sex and ethnicity) in the AAA and non-AAA
AAA
(n  1629)
Non-AAA
(n  63,348) P-value
2.10 [1.36; 2.83] 1.63 [1.38; 1.88] .0895
0.42 [0.10; 0.73] 0.43 [0.30; 0.55] .9244
0.37 [0.05; 0.69] 0.29 [0.18; 0.39] .6116
1.35 [0.74; 1.94] 0.93 [0.74; 1.11] .0412
1.52 [0.84; 2.19] 1.75 [1.49; 2.02] .7775
1.40 [0.73; 2.07] 1.20 [0.98; 1.41] .4482
5.02 [3.83; 6.19] 4.36 [3.96; 4.77] .1046
17.07 [14.98; 19.12] 12.26 [11.62; 12.88] .0001
16.59 [14.53; 18.60] 12.13 [11.50; 12.76] .0001
7.20 [5.73; 8.65] 7.12 [6.61; 7.62] .7712
2.82 [1.84; 3.79] 1.24 [1.02; 1.46] .0001
1.50 [0.83; 2.16] 0.86 [0.67; 1.04] .0060
4.27 [3.10; 5.43] 3.49 [3.13; 3.85] .1212
1.05 [0.48; 1.63] 0.63 [0.49; 0.80] .0499
3.71 [2.55; 4.84] 1.28 [1.06; 1.49] .0001
12.15 [10.52; 13.75] 8.39 [8.03; 8.75] .0001
5.18 [3.80; 6.55] 1.64 [1.39; 1.88] .0001
nce interval;CV, cardiovascular;MI,myocardial infarction; PAD, peripheralted f
)
)
er)individuals with known AAA suffer from both fatal and
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likely includes the spectrum of AAA-related events and
undiagnosed AAA rupture. Individuals with known AAA in
the REACH Registry also suffered high rates of heart
failure and hospitalization as a result of CV events and
procedures, which contributed to the morbidity of patients
with AAA. Data on surgical or endovascular AAA repair
were not specifically collected in case report forms so it is
not possible to evaluate the impact of AAA-repair on life
expectancy or prognosis in this study.
While the REACH Registry data demonstrate that
there was an intensification of use of risk-reduction medi-
cations in the AAA cohort compared with the non-AAA
cohort, the actual fractional use of these medications was
not very different from that used in the non-AAA cohort.
The rationale for increased use of oral vitamin K antagonists
is unknown, but could either relate to more vascular pro-
cedures performed or to more frequently recognized left
ventricular systolic dysfunction, presence of atrial fibrilla-
tion, or a history of prior thromboembolic events in the
AAA cohort (none of which was measured in this large
Registry). The trend toward use of more aggressive risk
reduction medication might be explained by a higher rate
of polyvascular disease in one-third of the REACHRegistry
AAA population. Pharmacologic treatments recently sug-
gested to prevent AAA expansion or rupture, namely statins
and angiotensin converting enzyme inhibitors,6,33,34 were
not more commonly prescribed in the AAA compared with
the non-AAA cohort in the REACH Registry.
Study limitations. Recruitment of patients into the
REACH Registry was determined by a strategy to enroll
individuals known to be at high risk of atherothrombotic
events and not by the presence of an AAA at baseline.
Although we cannot exclude potential selection bias at
enrollment, AAAwas not an inclusion criterion in REACH,
so we can reasonably infer that AAAs in the REACH
Registry are truly reflective of AAA in patients with athero-
thrombosis and the comparisons between the AAA cohort
and non-AAA cohort for risk factors and extent of athero-
thrombosis are unlikely to be biased. A selection bias re-
garding diagnosis of AAA was noticed for some specialties.
A diagnosis of AAA was obtained more frequently than
expected by endocrinologists and neurologists but less
frequently by general surgeons and vascular physicians.
However, as this selection bias represents less than one-
sixth of the REACH population, it was negligible for the
overall analysis. Moreover, as primary imaging was not
performed, a diagnosis of AAA may have been based on
physical examination, although this is rather unusual.
The REACH Registry is not a prospective, population-
based study and it provides a major platform for descriptive
analysis of the natural history of patients with recognized
AAA, but no data to describe the natural history of occult
AAA, as might be obtained from a screening study. Fur-
thermore, we note that subjects were classified as having an
AAA by physician report, and not based on systematic use
of any aortic imaging modality. The role of case misclassi-
fication is unknown. We presume that the actual prevalenceof AAA is underestimated by a factor of 2 compared with
systematic screening programs.8,20 In an international
study of this size, the costs and inconvenience associated
with baseline and follow-up aortic imaging would not be
sustainable. Another important limitation is the lack of
capture of “AAA rupture” as a separate event in the case
record form. Nonetheless, despite these limitations, find-
ings from the REACH Registry appear consistent with
insights derived from various regional AAA screening pro-
grams. Importantly, findings from the REACH Registry
extend knowledge of AAA-associated risk factors, polyvas-
cular arterial disease, and CV outcomes in this important
aortic disease cohort to a global public health context.
CONCLUSIONS
In individuals at risk of atherothrombotic events, AAA
is common in elderly, non-diabetic, White males with a
history of smoking. Individuals with AAA from this large
multinational cohort of patients with either overt manifes-
tations of CV disease or multiple risk factors suffer higher
rates of CV hospitalization and CV deaths than other
patients with atherothrombosis. The high morbidity and
mortality associated with AAA is derived not only from
AAA-associated rupture and death, but is presumably due
to the more advanced age, and a more widespread polyvas-
cular manifestation of atherothrombotic disease in affected
individuals. Results suggest that there is need to increase
awareness of AAA and its consequences, and to implement
screening protocols for patients at high risk for AAA. In
order to facilitate screening, solid risk factors are mandatory
to identify the population at risk.
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